DUBLIN, Ireland, April 27, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2017.
Quarter 1 Results
Total revenues for Q1, 2017 were $23.5m which was marginally higher than that recorded in Q1, 2016.
